Peptris Technologies: AI-Driven Drug Discovery in 2026
Discover how Peptris Technologies is revolutionizing drug discovery in 2026 with AI. Learn about their innovative approach and funding milestones.
LazyFounders
Peptris Technologies: Revolutionizing Drug Discovery with AI in 2026
30 SEC SUMMARY
In 2026, Peptris Technologies is at the forefront of AI-driven drug discovery, leveraging advanced machine learning to accelerate the development of novel therapeutics for oncology, inflammation, and rare diseases. The company has secured $9.0M in funding and is collaborating with global partners to bring innovative treatments to market faster.
TABLE OF CONTENTS
Introduction
In the rapidly evolving field of biotechnology, Peptris Technologies stands out as a pioneering force in AI-driven drug discovery. Founded in 2019, the company is revolutionizing the way new drugs are discovered and developed, aiming to reduce the time, cost, and complexity of bringing life-changing therapies to patients worldwide.
About Peptris Technologies
Peptris Technologies Private Limited is headquartered in Bangalore, Karnataka, India. The company operates on a B2B business model and employs fewer than 10 people. The core team includes:
- Narayanan Venkatasubramanian - Co-Founder
- Shridhar Narayanan - Co-Founder and Chief Scientific Advisor
- Amit Mahajan - Co-Founder
- Anand Budni - Co-Founder
Business Model and Funding
Peptris Technologies follows a Fee-For-Service business model, offering its AI-driven drug discovery services to pharmaceutical companies and biotech firms. The company has raised a total of $9.0M in funding, with notable investors including Tenacity Ventures, Indian Angel Network, and Speciale Invest.
AI-Powered Drug Discovery
Peptris leverages a proprietary AI and machine learning platform that combines unsupervised learning, generative AI, and large language model technologies to design, optimize, and prioritize drug candidates. This innovative approach enables the discovery of Novel Chemical Entities (NCEs), repurposing of approved drugs, and rescue of clinically validated molecules by predicting critical molecular properties and reducing the need for extensive wet-lab experimentation.
Partnerships and Collaborations
Operating through a virtual R&D model, Peptris collaborates with contract research organizations (CROs), biotechnology partners, academic institutions, and pharmaceutical companies to validate and advance its preclinical pipeline. The company has successfully built a portfolio of AI-discovered drug candidates, including assets targeting rare diseases and cancer, and has achieved significant milestones through strategic licensing partnerships and regulatory recognition.
Future Prospects
Looking ahead, Peptris aims to continue its mission of transforming the drug discovery process by delivering innovative, scalable, and data-driven solutions. With expertise spanning computational biology, medicinal chemistry, data science, and artificial intelligence, the company is well-positioned to drive significant advancements in the field of biotechnology.
Frequently Asked Questions
Where is Peptris headquartered?
Peptris is headquartered in Bangalore, Karnataka, India.
What is the business model of Peptris?
Peptris operates on a B2B business model, offering AI-driven drug discovery services.
What is the founding date of Peptris?
Peptris was founded in 2019.
How much funding has Peptris raised till date?
Peptris has raised a total of $9.0M in funding.
KEY HIGHLIGHTS
- Peptris uses AI to accelerate the discovery of novel therapeutics.
- The company has raised $9.0M in funding from notable investors.
- Peptris collaborates with global partners to bring innovative treatments to market.
Conclusion
Peptris Technologies is making significant strides in the field of AI-driven drug discovery, aiming to revolutionize the way new drugs are developed. With its innovative approach and strategic partnerships, Peptris is poised to deliver transformative solutions that will improve outcomes for patients worldwide.
Call-to-Action
For more startup stories and insights, visit blogy.in.
Sources
- yourstory.com
Peptris Company Profile Funding & Investors
This story is an original summary and analysis written by LazyFounders from the reporting listed above. Facts are attributed to their original publishers; sections marked as analysis are LazyFounders's opinion. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links.
